Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nicolas, Rezvoy"'
Autor:
Emine Canyilmaz, Brigitta G. Baumert, Nicolas Rezvoy, Salvador Villà, Ewa Szutowicz, Damien C. Weber, Deniz Yalman, Theo Veninga, René O. Mirimanoff, Marco Krengli, David Pasquier, Tzahala Tzuk-Shina, Stefan Bijmolt
Publikováno v:
International Journal of Radiation Oncology, Biology, Physics, Vol. 71, No 5 (2008) pp. 1388-1393
PURPOSE: To retrospectively analyze and assess the outcomes and prognostic factors in a large number of patients with atypical and malignant meningiomas. METHODS AND MATERIALS: Ten academic medical centers participating in this Rare Cancer Network co
Autor:
Magali, Rebucci, Paul, Peixoto, Amélie, Dewitte, Nicole, Wattez, Marie-Adeline, De Nuncques, Nicolas, Rezvoy, Claire, Vautravers-Dewas, Marie-Pierre, Buisine, Eric, Guerin, Jean-Philippe, Peyrat, Eric, Lartigau, Amélie, Lansiaux
Publikováno v:
International journal of oncology. 38(1)
EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC). Cetuximab is a monoclonal antibody designed to interact with EGFR, block its activation, reduce the downstream signaling pathways and induce EGFR internalization. This st
Autor:
Julia Salleron, E. Pape, Véronique Dziwniel, Xavier Mirabel, Sophie Darras, Veronique Martinot, Pierre Guerreschi, Laurent Mortier, Nicolas Rezvoy, Nicolas Penel
Publikováno v:
Journal of the American Academy of Dermatology. 65(5)
Background Merkel cell carcinoma (MCC) is a rare skin cancer. Cumulative data from retrospective series support the notion that benefits are obtained by both wide excision and adjuvant radiation therapy. However, surgery may be difficult to perform w
Autor:
Eric Lartigau, Charles Fournier, Nicolas Rezvoy, B. Prevost, Antoine Adenis, Xavier Mirabel, Bernard Coche-Dequeant, David Pasquier, Bernard Castelain, Genevieve Hecquet
Publikováno v:
International journal of radiation oncology, biology, physics. 65(5)
Purpose: The aim of this study was to retrospectively evaluate the feasibility, efficacy, and tolerance of external beam radiotherapy followed by high-dose-rate brachytherapy in inoperable patients with superficial esophageal cancer. Patients and Met